05:38 AM EDT, 10/20/2025 (MT Newswires) -- Exelixis ( EXEL ) on Monday reported detailed results of a phase 3 trial of zanzalintinib in combination with atezolizumab versus regorafenib in patients with previously treated non-microsatellite instability-high metastatic colorectal cancer.

The median overall survival in the intention-to-treat population was 10.9 months with the combination versus 9.4 months with regorafenib at a median follow-up of 18 months.

The company said it observed a trend for improvement in progression-free survival with the combination in the intention-to-treat population, "though statistical superiority cannot be claimed at this time due to the pre-specified hierarchical testing strategy."

Deaths considered pertaining to treatment by investigators were two for zanzalintinib, two for atezolizumab, one for the combination and one for regorafenib, the company said.

Exelixis ( EXEL ) shares were down 8.5% in recent premarket activity.